Clinical Trial Update: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) [Phase 3]

View source ↗

Summary

This Phase 3 INSPIRE 2 trial compares tildrakizumab with placebo in anti-TNF-naïve adults with active psoriatic arthritis, reporting on efficacy and safety. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Ilumya (tildrakizumab)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Active Psoriatic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING